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Structural studies of G protein-coupled receptors
(GPCRs) extensively use the insertion of globular
soluble protein domains to facilitate their crystalliza-
tion. However, when inserted in the third intracellular
loop (i3 loop), the soluble protein domain disrupts
their coupling to G proteins and impedes the GPCRs
functional characterization by standard G protein-
based assays. Therefore, activity tests of crystalliza-
tion-optimized GPCRs are essentially limited to their
ligand binding properties using radioligand binding
assays. Functional characterization of additional
thermostabilizing mutations requires the insertion
of similar mutations in the wild-type receptor to allow
G protein-activation tests. We demonstrate that ion
channel-coupled receptor technology is a comple-
mentary approach for a comprehensive functional
characterization of crystallization-optimized GPCRs
and potentially of any engineered GPCR. Ligand-
induced conformational changes of the GPCRs are
translated into electrical signal and detected by
simple current recordings, even though binding of
G proteins is sterically blocked by the added soluble
protein domain.
INTRODUCTION
G protein-coupled receptors (GPCRs) are membrane proteins
involved in cellular communications and environment sensing
in eukaryotic organisms. The specific binding of circulating
ligands is transduced inside the cell and amplified by intracel-
lular pathways leading to an adapted cellular response. Due
to their central role in human physiology as well as their abun-
dance (>800 human genes), GPCRs are major pharmaceutical
targets. With the dual objective of developing new pharmaceu-
tical compounds and understanding the complex molecular
mechanisms of signal transduction, high-resolution crystallo-
graphic structures of GPCRs provide invaluable data (KatritchStructure 22, 14et al., 2013). However, low expression level and intrinsic insta-
bility of GPCRs have proven to be major impediments to crys-
tallographic studies. Thus, the rhodopsin receptor, which is
naturally abundant in the photoreceptor cell outer segments
and stabilized in an inactive dark state by a covalently bound
ligand and an ionic lock, was the first GPCR structure deter-
mined, and remained the only one for a further 7 years until
the structure of the b2-adrenergic receptor was solved (Venka-
takrishnan et al., 2013). To solve GPCR structures other than
rhodospin, three successful methods have been used, alone
or in combination, to overcome receptor instability and increase
the solvent-exposed surface area available for crystal contacts:
(1) co-crystallization with stabilizing antibodies (Rasmussen
et al., 2007), including nanobodies (Rasmussen et al., 2011);
(2) insertion of T4 phage lysozyme (T4L; Cherezov et al.,
2007; Rosenbaum et al., 2007), thermostabilized apocyto-
chrome b562RIL (BRIL; Chun et al., 2012; Liu et al., 2012), or
rubredoxin (Tan et al., 2013) domains; (3) introduction of ther-
mostabilizing mutations (Warne et al., 2008). The T4L insertion
in the i3 loop has been so far the most successful strategy
with 14 distinct receptors crystallized in different states (Katritch
et al., 2013). Unfortunately, the insertion of a T4L or other solu-
ble protein fusion domain in the i3 loop disrupts interactions
with G proteins and hinders functional characterization of the
modified receptors with standard G protein-dependent
signaling assays (Liu et al., 2012; Wu et al., 2010). Testing the
function of engineered receptors is therefore limited to radioli-
gand binding and competition assays. However, these assays
evaluate only the proper folding of the ligand binding sites by
comparing affinities with the wild-type (WT) receptor. In the
case of the b2-adrenergic receptor, functional characterization
was completed by fluorescence spectroscopy of the bimane-
labeled Cys2656.27 b2(T4L) (Rosenbaum et al., 2007),
demonstrating ligand-induced conformational changes of the
cytoplasmic end of helix VI. These results were similar to those
observed with the WT b2-adrenergic receptor. This method of
fluorescence spectroscopy has not been used with other crys-
tallized GPCRs having a T4L or other fusion domain. In most
cases, the constructs providing the highest crystallographic
resolution required adjustments of the fusion partner insertion
sites (Kruse et al., 2012), which could affect the receptor
dynamics and lead to partially active or inactive states.9–155, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 149
Figure 1. Electrophysiological Character-
ization of the M2(T4L) Muscarinic Receptor
(A) Schematic representation of ICCR(T4L)
showing, in the plane of the membrane, one of the
4 subunits of the ICCR and the Kir6.2 part of the
facing subunit. Ligand-induced conformational
changes of T4L-modified GPCRs are transduced
into electrical signals by the fused Kir6.2 channel.
KD represents the Kir6.2DC36.
(B) Whole-cell basal current amplitudes reflect the
surface expression levels of M2 ICCRs. Bars
represent the mean ± SEM of whole-cell currents.
The dashed line represents the average endoge-
nous current recorded in noninjected oocytes.
Numbers of recordings are indicated above bars.
(C) Representative TEVC recordings at 50 mV
showing M2 ICCR responses to 5 mM ACh. Grey
and blue arrows indicate basal current and chan-
nel inhibition during ACh application, respectively.
Barium (Ba2+, 3 mM) is a generic blocker of po-
tassium channels used to determine the baseline
(dashed line).
(D) The antagonist atropine (1 mM, red line and
arrow) inhibits the effect of ACh.
(E) Percent inhibition induced by 5 mM ACh (blue
bar) and 5 mM Ach + 1 mM atropine (red bar).
Percentages are calculated in reference to the
current amplitude before ligand applications. Bars
represent mean ± SEM n = 6.
Structure
Functional Characterization of T4L-Modified GPCRsOccasionally, thermostabilizing mutations are incorporated in
the T4L-modified receptors in order to increase the resolution
of crystallographic structures. Such mutations can affect the
activity of GPCRs and their impact must be tested, usually by
inserting them in the WT receptor to perform standard G pro-
tein-based assays (White et al., 2012).
Building on the concept of ion channel-coupled receptors
(ICCRs; Caro et al., 2011, 2012; Moreau et al., 2008), we devel-
oped a functional assay for GPCRs by genetically fusing a potas-
sium channel to the receptor C terminus. The channel acts as a
direct reporter of the agonist- and antagonist-induced confor-
mational changes of the GPCRs. Upon binding of agonists, the
receptor undergoes conformational changes propagating from
the external ligand binding site to the intracellular side leading
to the activation of G proteins. In ICCRs, agonist binding induces
either activation (M2 and b2 ICCRs) or inhibition (D2 and Opsin
ICCRs) of the fused channel. Antagonists are detected by their
ability to block the agonist effect. Using G protein-blocking
toxins, current recordings in cell-free environment and co-
expression of unfused receptors and channels, we demon-
strated that the fused channel serves as a reporter of the
activated state of the GPCR (Moreau et al., 2008). Conforma-
tional changes induced by activation of the GPCR are trans-
mitted to the channel gate(s), resulting in stabilization of the
channel in open-state (activation) or in closed-state (inhibition).
Concentration-effect curves with agonists revealed a correlation
between the amplitude of the current and the concentration of
agonists, indicating that the affinity and the efficacy of a ligand
finely tuned the kinetics of channel gating. The generated
electrical signal is measured by electrophysiological methods
providing the following advantages: (1) low-cost and nonradio-
active reagents, (2) real-time recordings on single cells, (3)150 Structure 22, 149–155, January 7, 2014 ª2014 Elsevier Ltd All rigdetection of agonists and antagonists in concentration-depen-
dent manner, and (4) functional characterization of additional
thermostabilizing mutations in the T4L constructs. Most notably,
the ICCR technology is independent of G protein activation and
simplifies the functional characterization of engineered G
protein-(un)coupled receptors and additional mutations. In this
study, we demonstrate the potential of ICCR technology to func-
tionally characterize GPCRs optimized for crystallization by T4L
insertion in the i3 loop.
RESULTS
Proof of Concept: M2(T4L) Functional Characterization
The ability of ICCRs to functionally characterize GPCRs(T4L)
optimized for crystallization was first tested with the human M2
muscarinic receptor (Figure 1A). Starting from the human M2
receptor fused to Kir6.2, the T4L domainwas genetically inserted
to produce a receptor identical to the crystallized M2(T4L) (Haga
et al., 2012) with the exception of two differences: (1) the glyco-
sylation sites were not removed; and (2) the last nine residues
were removed creating an agonist-inhibited ICCR.
ICCRs were heterologously expressed in Xenopus oocytes by
microinjection of mRNA. Whole-cell currents were recorded by
manual or automated two-electrode voltage-clamp (TEVC) in
symmetrical high K+ concentrations. The surface expression of
ICCRs was roughly estimated by the amplitude of the basal
current in the absence of ligands. Results presented in Figure 1B
reveal that the insertion of T4L unexpectedly abolished surface
expression of the muscarinic ICCR. Physiologically, surface
expression of Kir6.2 requires a physical interaction with the sul-
fonylurea receptor, its natural partner, in order to mask an endo-
plasmic reticulum (ER) retention signal, the Arg-Lys-Arghts reserved
Figure 2. Role of the i3 Loop in the Efficacy
of Agonist on M2 ICCRs
(A) Concentration-dependent inhibition of M2
ICCRs by carbachol (CCh, an ACh analog).
Increasing concentrations of CCh are applied on
the same cell expressing the indicated constructs.
M2 + KD corresponds to the co-expression of the
unfusedM2 receptor and Kir6.2DC36 channel.Di3
signifies deletion of the i3 loop. Values are mean ±
SEM. Negative values indicate an inhibition of the
current generated by Kir6.2. nR 7.
(B) Whole-cell basal currents including M2(Di3)-K
ICCR. Bars represent the mean ± SEM. Numbers
of recordings are indicated above bars.
(C) Co-expression of the G protein-activated
Kir3.4* channel with the i3 loop-lacking ICCR,
M2(Di3)-K. Due to a higher surface expression
level of the Kir3.4* channel, the current amplitude
generated by this channel is much larger than the
current generated by Kir6.2. TEVC recordings
show that binding of ACh (5 mM) to the fused
M2(Di3) receptor activates the Kir3.4* channels
demonstrating that this modified receptor is able
to activate Gi/o proteins.
(D) Mean ± SEM of the percentage of activation of
Kir3.4* induced by 5 mM Ach on cells expressing
M2 and M2(Di3) ICCRs.
Structure
Functional Characterization of T4L-Modified GPCRssequence, present in the channel cytoplasmic C terminus (Zer-
angue et al., 1999). Removal of this signal by truncation of the
last 36 residues of Kir6.2, denoted KD, allows surface expression
of the channel alone (Tucker et al., 1997). We found that such
removal in the ICCR(T4L) was beneficial and the construct
M2(T4L)-KD displayed high surface expression (Figure 1B).
This is in contrast with our previous observation that the pres-
ence of the ER retention signal did not preclude high surface
expression of M2 ICCRs (Moreau et al., 2008), suggesting that
the insertion of the T4L domain in M2 receptor affects the mask-
ing of the channel ER retention signal.
Ligand-induced conformational changes are detected by the
change of current generated by the fused Kir6.2 channel. In
ICCRs, the open probability of Kir6.2 is similar to that of the
unfused channel (KD) and the channel is partly open at rest in
our experimental conditions. This basal activity offers the advan-
tage of sensing either agonist-evoked channel inhibition (short-
ened M2, rhodopsin and D2L ICCRs; Caro et al., 2012; Moreau
et al., 2008) or activation (full-length M2, b2 ICCRs; Caro et al.,
2011; Moreau et al., 2008). In the case of the M2(T4L) ICCR,
the physiological agonist acetylcholine (ACh) causes an inhibi-
tion of Kir6.2 comparable to that observed with the WT M2
ICCR (Figure 1C). This result demonstrates the ability of this
system to detect agonist-induced conformational changes of
M2(T4L) receptor by simple current recording. Antagonists are
also detected by M2 and M2(T4L) ICCRs, as shown in Figures
1D and 1E with atropine (1 mM) being concomitantly applied
with ACh (5 mM). Functional characterization of M2(T4L) receptor
was completed with concentration-response curves (Figure 2A)
for carbachol (CCh), a synthetic agonist, showing that T4L inser-
tion does not change the affinity reported by the ICCR assay.
This result is in agreement with competitive radioligand bindingStructure 22, 14assays performed on M2 and M2(T4L) receptors (Haga et al.,
2012). We note that the insertion of T4L reduced the efficacy of
the agonist, as shown by the lower amplitude of the ICCR signal.
Engineering the GPCRs with the T4L domain generates two
modifications: (1) deletion of the i3 loop and (2) insertion of the
T4L domain. In order to discriminate between the effect of i3
loop deletion and that of the T4L addition on the lower efficacy
of the agonist on the M2(T4L) ICCR, we created a M2 ICCR
without the i3 loop (M2(Di3)-K) and performed a CCh-concentra-
tion effect curve. Figure 2A shows a similar curve for the T4L and
the Di3 constructs indicating that the lower observed efficacy is
due to the deletion of the i3 loop and not to the addition of the
T4L domain. In contrast, surface expression of M2(Di3)-K,
despite the presence of the ER retention signal (Figure 2B), indi-
cates that the lack of expression of M2(T4L)-K is due to the
insertion of the T4L domain and not to the deletion of the i3
loop. The insertion of the T4L domain in the i3 loop disrupts
the interaction with G proteins as observed for all crystallized
GPCR(T4L), while the deletion of the i3 loop preserves the ability
of the receptor to activate G proteins, as verified by the activa-
tion of G protein-activated Kir3.4 channels (Figures 2C and 2D).
This observation raises the hypothesis that surface expression
of M2 ICCRs requires interaction with partners such as G pro-
teins able to mask the Kir6.2 ER retention signal and that this
interaction is disrupted by the T4L domain when inserted in
the i3 loop.
Validation with Another GPCR: b2(T4L) ICCR
We demonstrated that ICCR technology is able to functionally
characterize M2(T4L) receptor. To validate this concept
with another GPCR, we used the previously created adrenergic
b2-K ICCR (Caro et al., 2011) and inserted the T4L domain in9–155, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 151
Figure 3. Characterization of another GPCR(T4L): The b2(T4L) Adrenergic Receptor
(A) Schematic representations of b2(T4L) ICCR.
(B) Whole-cell basal currents generated by the indicated constructs. Implicitly, all b2 ICCRs were co-expressed with the N-terminal domain of the sulfonylurea
receptor 1 (TMD0) to boost their surface expression as previously described. Values are mean ± SEM. Numbers above bars represent the number of oocytes
tested.
(C) TEVC recordings showing the activation of the fused Kir6.2 (brown arrows) by the adrenergic agonist isoproterenol 0.5 mM in cells expressing b2 and b2(T4L)
ICCRs.
(D) Percentage of activation of b2 constructs by 0.5 mM isoproterenol. Values are mean ± SEM and the number of experiments is indicated over the bars.
(E) Concentration-effect curves of isoproterenol on the indicated b2 ICCRs and the control with the unfused receptor and channel (b2 + KD). Values are mean ±
SEM nR 5.
Structure
Functional Characterization of T4L-Modified GPCRsthe i3 loop (Figure 3A). The position of the T4L domain was the
same as in the first crystallized b2(T4L) receptor (Rosenbaum
et al., 2007), but the glycosylation sites were left intact. Removal
of the Kir6.2 ER retention signal was required to detect the
b2(T4L)-K ICCR at the cell surface, as observed for the M2
ICCR (Figure 3B). The b2 ICCRs have the particularity to require
the co-expression of the transmembrane domain 0 (TMD0) from
the sulfonylurea receptor 1 (SUR1; Caro et al., 2012), and its
presence is implicit with all b2 ICCRs. TMD0 tightly binds to the
Kir6.2 channel (Chan et al., 2003), presumably acting as a chap-
erone on ICCRs.
In this configuration, the activation of b2 receptor by 0.5 mM
isoproterenol, an adrenergic agonist, leads to the activation of
Kir6.2 (Caro et al., 2011). Applied on the b2(T4L)-K ICCR (Figures
3C and 3D), the agonist induced the same response, validating
the ICCR functional assaywith a secondGPCR(T4L). Comparison
of the agonist concentration-effect curvesofb2 and b2(T4L) recep-
tors (Figure 3E) confirmed the results obtainedwithM2(T4L) ICCR:
similar apparent affinities but lower efficacy of the T4L construct.152 Structure 22, 149–155, January 7, 2014 ª2014 Elsevier Ltd All rigExtrapolation to a Not-Yet-Crystallized GPCR:
OXTR(T4L) ICCR
To validate this method with a third receptor not yet crystallized,
we chose the oxytocin receptor (OXTR) as a model (Figure 4A).
This receptor has been optimized for crystallization with the
following modifications: (1) i3 loop replacement by the T4L
domain, (2) C-terminal truncation of the last 42 residues, and
(3) gene optimization for expression in insect cells. As for M2
and b2 receptors, surface expression of the OXTR(T4L) ICCR
required the elimination of the Kir6.2 ER retention signal (Fig-
ure 4B), confirming the deleterious effect of the T4L domain on
the surface expression of ICCRs.
The application of the natural agonist, oxytocin (1 mM), trig-
gered a large activation of the Kir6.2 channel (Figures 4C and
4D), confirming the ability of the ICCR to also detect the confor-
mational changes of this receptor in a concentration-dependent
manner (Figure 4E). Comparison with the WT receptor was not
possible because the WT OXTR ICCR produced no detectable
signal. One reason for this could be a high basal activity ofhts reserved
Figure 4. Application of the ICCR Functional Assay to a Not-Yet-Crystallized GPCR: The Oxytocin Receptor
(A) Diagram of oxytocin ICCR OXTR(T4L)-K.
(B) Assessment of the surface expression of the OXTR(T4L) ICCR by measuring the whole-cell basal current. Bars represent mean ± SEM and numbers above
bars, the number of recordings.
(C) TEVC recordings showing the activation of the ICCR during application of the agonist oxytocin 1 mM.
(D) Statistical results represented as mean ± SEM of percentage of change in current induced by 1 mM oxytocin.
(E) Concentration-effect curves of oxytocin on cells expressing OXTR(T4L)-KD or KD. Values are mean ± SEM nR 6.
Structure
Functional Characterization of T4L-Modified GPCRsOXTR in our experimental conditions, a persistent activation of
Gq-proteins and, in turn, phospholipase C, which hydrolyzes
the phosphatidylinositol 4,5-bisphosphate (PIP2; Kobrinsky
et al., 2000) required for the opening of Kir6.2. Other potential
explanations could include an improper folding of the WT
OXTR ICCR or artificial oligomeric status leading to inactivity of
the channel. However, it is unlikely that insertion of the T4L
domain would correct the folding or the oligomeric status of
the OXTR ICCR.
DISCUSSION
These results demonstrate the ability of the ICCR technology to
assess the functionality of G protein-’’uncoupled’’ receptors that
contain the insertion of the T4L domain in the i3 loop. Compared
to the functional assays currently used for such engineered
GPCRs (radioligand binding and fluorescence spectroscopy of
bimane probes), ICCRs offer complementary advantages by re-
porting global conformational changes of GPCRs occurring
between the ligand binding sites and the G protein interaction
sites. Thus, we discovered that GPCRs(T4L) display a partial
agonist phenotype (lower agonist-efficacy), probably due to
the absence of the i3 loop because the same phenotype is
observed for an ICCR lacking this domain. Interestingly, among
the seven different GPCRs crystallized in an agonist-bound state
(rhodopsin, b1 and b2 adrenergic, A2A, NTSR1, 5-HT1B, and 5-Structure 22, 14HT2B receptors), five were engineered with the T4L or BRIL
domain inserted in their i3 loop (b2 adrenergic, A2A, NTSR1,
5-HT1B, and 5-HT2B receptors; Venkatakrishnan et al., 2013)
and seems to display an intermediate active state. A recent
nuclear magnetic resonance study of b2 receptor (Kim et al.,
2013) reveals not only several active and inactive states, but
also an intermediate active state with a full agonist due to the
absence of interaction with a G protein or its mimic, the nano-
body Nb80. This finding reinforces the interpretation that the
full agonist isoproterenol generated an intermediate active state
of the b2(T4L) receptor due to the absence of G protein inter-
action. This partial agonist effect was detected with the ICCR
assays. Surprisingly, the same partial agonist effect is observed
for theM2(Di3) ICCRwhich is still able to interact with G proteins.
This suggests that the i3 loop would be required to stabilize the
receptor in the full-agonist active state.
Concentration-effect curves provided half-maximal effective
concentrations (EC50s) of 1.6 mM (carbachol) for M2, 141 nM
(isoproterenol) forb2, and1.5mM(oxytocin) forOXTR(T4L) ICCRs.
In the literature, values of EC50 are quite dispersed depending on
the assay and the cells used. However, cAMP assays performed
on mammalian cells provide similar EC50s for M2 (carbachol:
2.4 mM; Kovacs et al., 1998) and b2 (isoproterenol: 80 nM; Scott
et al., 1999). The EC50 for OXTR determined with inositol phos-
phate accumulation assay in mammalian cells is two orders of
magnitude lower (oxytocin: 10 nM; Corbani et al., 2011).9–155, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 153
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Functional Characterization of T4L-Modified GPCRsLigand binding to OXTR is highly dependent on cholesterol
that is present in the plasma membrane of Xenopus oocytes
(Hill et al., 2005). The lower apparent affinity observed in the
OXTR(T4L) ICCR could be related to a partial masking of the
cholesterol binding sites induced by the fusion with the channel.
By extrapolation, this technology could be relevant for the
characterization or structure-function studies of GPCRs with
impaired G protein binding generated by insertion of other glob-
ular soluble protein domains (Chun et al., 2012) in the cyto-
plasmic loops or by site-directed mutagenesis (Liu et al.,
1996). Indeed, we demonstrated in this study with GPCR(T4L),
and in previous studies by inhibition of Gi/o protein activation
with pertussis toxin, and in cell-free recordings (excised
outside-out patch-clamp mode), that the electrical signal gener-
ated by the fused Kir6.2 channel is independent of G protein
activation. Based on this property, ICCR technology has the
potential to detect ligand-induced conformational changes of
engineered G protein uncoupled receptors.
This technology is also suitable to automation using voltage-
clamp robots such as the HiClamp setup (Multichannel Systems
GmbH). Assays are performed in a 96-well plate format and
the characterization of one oocyte plate is completed in less
than 3 hr.
This method is currently validated on class A (rhodopsin-like)
GPCRs with the prerequisite of protein engineering to create
functional ICCRs. However, ICCR technology has now been
applied to a number of distinct receptors (Caro et al., 2011,
2012; Moreau et al., 2008), and simple building rules have
emerged that should greatly simplify its application to a wide
range of receptors.
We focused in this work on the set of GPCRs where a small
domain is inserted in the intracellular loop 3. This set is certainly
limited but it represents the large majority of GPCRs of known
structure and is likely to expand as more and more GPCR
structures are published. As demonstrated here, the method is
appropriate for i3 loop-modified GPCRs; it will also be useful




Ion channel-coupled receptors were created by the genetic fusion of GPCR
genes to the 50 extremity of the mouse KCNJ11 gene (Kir6.2) cloned in a modi-
fied pGEMHE Xenopus oocytes vector (pGH2). For biochemical detection, a
hemagglutinin tag extended by 11 residues (Schwappach et al., 2000) is pre-
sent in the extracellular loop of Kir6.2. GPCR insertion was performed by a
two-step polymerase chain reactions (PCRs) using hybrid primers with com-
plementary GPCR sequences at the 30 end and final template sequences in
50. All PCRs were prepared with the Quikchange Lightning kit (Agilent Technol-
ogies). The first PCR amplifies the full length GPCR genewithout consideration
of the original vector. After in-gel DNA-purification using Geneclean turbo kit
(MP Biomedicals), the PCR product serves as a ‘‘megaprimer’’ for a second
PCR using the final template Kir6.2 pGH2. As previously reported, truncation
of the first 25 residues of the channel provides the optimal functional coupling
with fused GPCRs (Moreau et al., 2008). Consequently, all GPCRs were fused
to the DN25Kir6.2 channel. The human M2 muscarinic and the b2 adrenergic
ICCRs were already available at the beginning of the project and the T4L
domain was inserted by the two-step PCR described above using the
b2(T4L) receptor D1 construct (Rosenbaum et al., 2007) as the original tem-
plate. The last nine residues from M2 were truncated in M2-K and M2(T4L)-
KD generating agonist-inhibited ICCRs. In b2-K and b2(T4L)-KD, the last 62154 Structure 22, 149–155, January 7, 2014 ª2014 Elsevier Ltd All rigresidues were truncated to generate functional coupling between the receptor
and the channel (Caro et al., 2011). Expression of b2 ICCRs required co-
expression of the first transmembrane domain (TMD0) of the sulfonylurea
receptor SUR1, a physiological partner of Kir6.2 (Caro et al., 2011; Chan
et al., 2003). Concerning the human oxytocin receptor, the OXTR(T4L) gene
was codon-optimized for insect cell expression, its last 42 residues were
removed and the influenza A virus hemagglutinin signal sequence was inserted
at its N terminus (Liu et al., 2012).
The final DNA constructs were identified by restriction profile and verified by
DNA sequencing (Beckman Coulter Genomics). After overnight linearization
and standard phenol/chloroform extraction, mRNA synthesis was performed
by in vitro transcription (mMessage mMachine T7 kit, Ambion) and purified
by the same phenol/chloroform method. Quantitative and qualitative controls
of the RNA samples were done by electrophoresis and UV spectrophotometry
(Nanodrop2000c, Thermo Scientific).
To test the ability of M2(Di3)-K to activate Gi/o proteins, we co-expressed
the ICCR with a G protein-activated channel, Kir3.4*, which was mutated to
form an homotetramer (Vivaudou et al., 1997). Surface expression of the
Kir3.4* channel being much higher than the ICCR, the current generated by
Kir3.4* is predominant and displays clear activation of this channel by the
endogenous Gi/o proteins.
Heterologous Expression in Xenopus oocytes
mRNAs were diluted in RNase-free water and micro-injected, either manually
(Nanoject, Drummond) or automatically (RoboInject, Multi Channel Systems).
Each oocyte received a volume of 50 nl containing the following quantity of
mRNA: 4 ng of ICCRs, 2.5 ng of TMD0, and 2 ng of Kir channels. Oocytes
were surgically removed from anesthetized Xenopus laevis females using
procedures that conformed to European regulations for animal handling and
experiments, and were approved by governmental services (authorization
no. 38 08 10 granted to Michel Vivaudou by the local veterinary agency, Direc-
teur De´partemental des Services Ve´te´rinaires, Ministe`re de l’Agriculture et de
la Peˆche, on February 22, 2008, valid until July 6, 2015) and the Institutional
Ethical Committee (Ethical Committee of Commissariat a` l’Energie Atomique
et aux Energies Alternatives for animal experiments, assessment no. 12-040
on December 23, 2012).
Oocytes were isolated by enzymatic defolliculation in 2 mg/ml type 1A colla-
genase (Sigma-Aldrich, C9891) solution gently shaken for 2 hr at 19C.
Oocytes in stage V and VI were selected and stored overnight at 19C in
Barth’s solution (1 mM KCl, 0.82 mM MgSO4, 88 mM NaCl, 2.4 mM NaHCO3,
0.41mMCaCl2, and 16mMHEPES, pH 7.4) supplementedwith 100 U/ml peni-
cillin, streptomycin, and gentamycin.
Microinjected oocytes were incubated individually in 96-well plates contain-
ing Barth’s solution with antibiotics, for more than 2 days at 19C.
Whole-Cell Current Recordings
Whole-cell currents were recorded using the two-electrode voltage clamp
(TEVC) technique. Two setups were used. (1) A standard manual setup
composed of a GeneClamp 500 amplifier (Molecular Devices), a digidata
1440A digitizer (Molecular Devices), an 8-reservoir gravity-flow perfusion
system with the electrovalve Valvelink 8.2 controller (AutoMate Scientific).
The voltage protocol was a succession of 5 s sweeps with alternating
500 ms steps to 50 mV, 0 mV, and +50 mV from a holding potential of
0 mV (Only the values at 50 mV were used for statistics and figures). Drug
application was by bath perfusion. Voltage protocols and current recordings
were performed with the pClamp10.0 software (Axon). (2) An automatic setup
consisting of the HiClamp robot (Multi Channel Systems). The voltage protocol
was identical to that used with the manual set-up. Drug application was per-
formed by immersion of each oocyte in continuously stirred 200 ml reservoirs
(from a 96-well plate) containing the test solutions. Membrane voltage was
clamped at 50 mV and current was recorded with the dedicated software.
Microelectrodes were made by pulling borosilicate capillaries (Kimble
Chase no. 34502 99 for manual setup orWPI no. TW150F-4 for the robot) using
a P-97 micropipette puller (Sutter Instrument) and filled with filtered 3 M KCl.
Oocytes were bathed in the following high potassium solution: 91 mM KCl,
1.8mMCaCl2, 1mMMgCl2, 5mMHEPES, and 0.3mMniflumic acid (a blocker
of endogenous calcium-activated chloride channels), at pH 7.4. The basal cur-
rent, taken as the current measured in the first minute of recording, served as ahts reserved
Structure
Functional Characterization of T4L-Modified GPCRsrough estimate of the number of channels at the cell surface (Kir6.2 are partially
open at rest in our conditions). Concentration-response experiments were
obtained by subsequent applications of increasing concentrations of ligands.
Fitting of Hill equation to the data was done with Origin 8 (OriginLab Corp.)
without constraints on Hill coefficient and dissociation constant. All data
shown represent the currents measured at 50 mV. All experiments were
repeated on different oocytes from different batches at room temperature.
All statistics show mean ± SEM and statistical significance was established
with unpaired two-tailed Student’s t tests.
ACKNOWLEDGMENTS
We are grateful to D. Rosenbaum and B. Kobilka for the b2AR(T4L) construct,
S. Seino for mouse Kir6.2, and K. Chan for the TMD0(SUR1)-F195 construct.
This work was supported by grants from the Agence Nationale de la
Recherche (ICCR project, grant ANR-09-PIRI-0010 and VenomPicoScreen
project, grant ANR-11-RPIB-022-04) and the Nanosciences Foundation
(NanoBioDrop project) to M.V., National Institutes of Health grant GM089857
to V.C., a studentship from the Region Rhone-Alpes to K.N., and a studentship
from the French Ministry of Research to L.N.C. The Grenoble laboratory is a
member of the French National Laboratory of Excellence (Ion Channel Science
and Therapeutics) supported by a network grant from ANR.
Received: August 10, 2013
Revised: September 24, 2013
Accepted: October 7, 2013
Published: November 21, 2013
REFERENCES
Caro, L.N., Moreau, C.J., Revilloud, J., and Vivaudou, M. (2011).
b2-Adrenergic ion-channel coupled receptors as conformational motion
detectors. PLoS ONE 6, e18226.
Caro, L.N., Moreau, C.J., Estrada-Mondrago´n, A., Ernst, O.P., and Vivaudou,
M. (2012). Engineering of an artificial light-modulated potassium channel.
PLoS ONE 7, e43766.
Chan, K.W., Zhang, H., and Logothetis, D.E. (2003). N-terminal transmem-
brane domain of the SUR controls trafficking and gating of Kir6 channel
subunits. EMBO J. 22, 3833–3843.
Cherezov, V., Rosenbaum, D.M., Hanson, M.A., Rasmussen, S.G., Thian, F.S.,
Kobilka, T.S., Choi, H.J., Kuhn, P., Weis, W.I., Kobilka, B.K., and Stevens, R.C.
(2007). High-resolution crystal structure of an engineered human beta2-adren-
ergic G protein-coupled receptor. Science 318, 1258–1265.
Chun, E., Thompson, A.A., Liu, W., Roth, C.B., Griffith, M.T., Katritch, V.,
Kunken, J., Xu, F., Cherezov, V., Hanson, M.A., and Stevens, R.C. (2012).
Fusion partner toolchest for the stabilization and crystallization of G protein-
coupled receptors. Structure 20, 967–976.
Corbani, M., Trueba, M., Stoev, S., Murat, B., Mion, J., Boulay, V., Guillon, G.,
and Manning, M. (2011). Design, synthesis, and pharmacological character-
ization of fluorescent peptides for imaging human V1b vasopressin or oxytocin
receptors. J. Med. Chem. 54, 2864–2877.
Haga, K., Kruse, A.C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang,
C., Weis, W.I., Okada, T., Kobilka, B.K., Haga, T., and Kobayashi, T. (2012).
Structure of the human M2 muscarinic acetylcholine receptor bound to an
antagonist. Nature 482, 547–551.
Hill, W.G., Southern, N.M., MacIver, B., Potter, E., Apodaca, G., Smith, C.P.,
and Zeidel, M.L. (2005). Isolation and characterization of the Xenopus oocyte
plasma membrane: a new method for studying activity of water and solute
transporters. Am. J. Physiol. Renal Physiol. 289, F217–F224.
Katritch, V., Cherezov, V., and Stevens, R.C. (2013). Structure-function of the
G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 53,
531–556.
Kim, T.H., Chung, K.Y., Manglik, A., Hansen, A.L., Dror, R.O., Mildorf, T.J.,
Shaw, D.E., Kobilka, B.K., and Prosser, R.S. (2013). The role of ligands on
the equilibria between functional states of a G protein-coupled receptor.
J. Am. Chem. Soc. 135, 9465–9474.Structure 22, 14Kobrinsky, E., Mirshahi, T., Zhang, H., Jin, T., and Logothetis, D.E. (2000).
Receptor-mediated hydrolysis of plasma membrane messenger PIP2 leads
to K+-current desensitization. Nat. Cell Biol. 2, 507–514.
Kovacs, I., Yamamura, H.I., Waite, S.L., Varga, E.V., and Roeske, W.R. (1998).
Pharmacological comparison of the cloned human and rat M2 muscarinic
receptor genes expressed in the murine fibroblast (B82) cell line.
J. Pharmacol. Exp. Ther. 284, 500–507.
Kruse, A.C., Hu, J., Pan, A.C., Arlow, D.H., Rosenbaum, D.M., Rosemond, E.,
Green, H.F., Liu, T., Chae, P.S., Dror, R.O., et al. (2012). Structure and
dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552–556.
Liu, J., Blin, N., Conklin, B.R., and Wess, J. (1996). Molecular mechanisms
involved in muscarinic acetylcholine receptor-mediated G protein activation
studied by insertion mutagenesis. J. Biol. Chem. 271, 6172–6178.
Liu, W., Chun, E., Thompson, A.A., Chubukov, P., Xu, F., Katritch, V., Han,
G.W., Roth, C.B., Heitman, L.H., IJzerman, A.P., et al. (2012). Structural basis
for allosteric regulation of GPCRs by sodium ions. Science 337, 232–236.
Moreau, C.J., Dupuis, J.P., Revilloud, J., Arumugam, K., and Vivaudou, M.
(2008). Coupling ion channels to receptors for biomolecule sensing. Nat.
Nanotechnol. 3, 620–625.
Rasmussen, S.G., Choi, H.J., Rosenbaum, D.M., Kobilka, T.S., Thian, F.S.,
Edwards, P.C., Burghammer, M., Ratnala, V.R., Sanishvili, R., Fischetti, R.F.,
et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-
coupled receptor. Nature 450, 383–387.
Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka,
T.S., Thian, F.S., Chae, P.S., Pardon, E., Calinski, D., et al. (2011). Crystal struc-
ture of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549–555.
Rosenbaum, D.M., Cherezov, V., Hanson, M.A., Rasmussen, S.G., Thian, F.S.,
Kobilka, T.S., Choi, H.J., Yao, X.J., Weis,W.I., Stevens, R.C., and Kobilka, B.K.
(2007). GPCR engineering yields high-resolution structural insights into beta2-
adrenergic receptor function. Science 318, 1266–1273.
Schwappach, B., Zerangue, N., Jan, Y.N., and Jan, L.Y. (2000). Molecular
basis for K(ATP) assembly: transmembrane interactions mediate association
of a K+ channel with an ABC transporter. Neuron 26, 155–167.
Scott, M.G., Swan, C., Jobson, T.M., Rees, S., and Hall, I.P. (1999). Effects of a
range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP
and on cyclic AMP driven gene expression in cultured human airway smooth
muscle cells. Br. J. Pharmacol. 128, 721–729.
Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G.W., Kufareva, I., Li, T., Ma, L., Fenalti,
G., Li, J., et al. (2013). Structure of the CCR5 chemokine receptor-HIV entry
inhibitor maraviroc complex. Science 341, 1387–1390.
Tucker, S.J., Gribble, F.M., Zhao, C., Trapp, S., and Ashcroft, F.M. (1997).
Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of
the sulphonylurea receptor. Nature 387, 179–183.
Venkatakrishnan, A.J., Deupi, X., Lebon, G., Tate, C.G., Schertler, G.F., and
Babu, M.M. (2013). Molecular signatures of G-protein-coupled receptors.
Nature 494, 185–194.
Vivaudou, M., Chan, K.W., Sui, J.L., Jan, L.Y., Reuveny, E., and Logothetis,
D.E. (1997). Probing the G-protein regulation of GIRK1 and GIRK4, the two
subunits of the KACh channel, using functional homomeric mutants. J. Biol.
Chem. 272, 31553–31560.
Warne, T., Serrano-Vega, M.J., Baker, J.G., Moukhametzianov, R., Edwards,
P.C., Henderson, R., Leslie, A.G., Tate, C.G., and Schertler, G.F. (2008).
Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 454,
486–491.
White, J.F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., Gvozdenovic-
Jeremic, J., Shah, P., Shiloach, J., Tate, C.G., and Grisshammer, R. (2012).
Structure of the agonist-bound neurotensin receptor. Nature 490, 508–513.
Wu, B., Chien, E.Y., Mol, C.D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R.,
Brooun, A., Wells, P., Bi, F.C., et al. (2010). Structures of the CXCR4 chemo-
kine GPCR with small-molecule and cyclic peptide antagonists. Science
330, 1066–1071.
Zerangue, N., Schwappach, B., Jan, Y.N., and Jan, L.Y. (1999). A new ER traf-
ficking signal regulates the subunit stoichiometry of plasmamembrane K(ATP)
channels. Neuron 22, 537–548.9–155, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 155
